Drug or treatment

Osimertinib clinical trials

• 62Clinical trials
• 2New in 30 days
• 30Countries

Newest trials

All recruiting trials (62)

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Osimertinib with Cyclosporine A for EGFR-mutant NSCLC

  This phase II study tests whether adding cyclosporine A to osimertinib helps people with EGFR-mutant metastatic NSCLC who still have detectable tumor DNA in blood.

  Recruiting Phase 2 NYU Langone Health · New York, New York · NCT07874490

• Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic NSCLC

  This trial tests whether surgically removing the main lung tumor, after initial osimertinib therapy, helps people with EGFR-mutant oligometastatic non-small cell lung cancer live longer without disease progression.

  Recruiting Phase 3 National Taiwan University Hospital · Taipei, Taipei City · NCT07738172

• Izalontamab Brengitecan with Osimertinib in EGFR-mutant NSCLC: first-line versus standard options

  This study tests whether adding iza-bren to osimertinib can help people with newly diagnosed EGFR-mutant non-small cell lung cancer, compared with osimertinib alone or osimertinib plus platinum-based chemotherapy.

  Recruiting at 10 sites Phase 3 Bristol-Myers Squibb · Beverly Hills, California and 204 other locations · NCT07680790

• BL-B01D1 with Osimertinib before/around surgery for EGFR-mutant resectable NSCLC

  A Phase II/III trial tests if adding BL-B01D1 to osimertinib around surgery helps people with resectable EGFR-mutant non-small cell lung cancer.

  Recruiting at 2 sites Phase 2/3 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality and 1 other locations · NCT07642024

• BL-B01D1 plus osimertinib vs osimertinib alone in unresectable EGFR-mutated NSCLC (Stage III) after chemoradiation

  This trial tests whether adding BL-B01D1 to osimertinib helps people with unresectable Stage III EGFR-mutated non-small cell lung cancer who did not progress after platinum-based chemoradiation.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT07640789

• Barriers and facilitators to sticking with osimertinib after early-stage NSCLC

  This study asks how adults with early-stage NSCLC in China continue or stop adjuvant osimertinib, by talking with patients and doctors to understand what helps or hinders persistence.

  Recruiting AstraZeneca · Beijing · NCT07542210

• Ivonescimab with datopotamab deruxtecan or osimertinib for EGFR‑mutant non‑small cell lung cancer

  This trial will test whether combining ivonescimab with datopotamab deruxtecan or with osimertinib is safe and helps people with metastatic EGFR‑mutant non‑small cell lung cancer who have already received third‑generation EGFR inhibitors and chemotherapy.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07535437

• Hippocampus-protective radiotherapy combined with osimertinib for symptomatic brain metastases in EGFR-mutated lung cancer

  This trial tests whether hippocampal-sparing whole-brain radiotherapy with a higher-dose simultaneous boost to brain tumors plus daily osimertinib can better control symptomatic brain metastases in people with newly diagnosed EGFR-sensitive non-small cell lung cancer.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07505173

• Boosting Osimertinib brain penetration with febuxostat in EGFR-mutated NSCLC

  This study tests whether adding febuxostat to osimertinib can increase osimertinib levels in the brain for patients with EGFR-mutated NSCLC who do not have CNS metastases.

  Recruiting Phase 2 Maastricht University Medical Center · Amsterdam and 1 other locations · NCT07485452

• Local ablative therapy added to osimertinib for EGFR‑mutant metastatic NSCLC with few remaining tumor sites

  This trial tests whether adding local ablative therapy to ongoing osimertinib helps people with EGFR exon 19 or exon 21 L858R mutated stage IV non‑small cell lung cancer who have three or fewer active tumor sites after initial treatment.

  Recruiting Phase 2 Chinese University of Hong Kong · Hong Kong · NCT07379476

• Osimertinib plus sacituzumab tirumotecan for EGFR-mutant advanced non-small cell lung cancer with persistent ctDNA after initial osimertinib

  This trial will test whether adding sacituzumab tirumotecan to osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer whose blood ctDNA remains positive after one cycle of osimertinib.

  Recruiting at 4 sites Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong and 3 other locations · NCT07375316

• Reasons for recurrence after adjuvant osimertinib in surgically removed EGFR-mutated lung cancer

  This project looks for genetic and clinical reasons why people with EGFR-mutated lung cancer who had surgery and adjuvant osimertinib later had their cancer come back, using tissue and blood samples taken at recurrence.

  Recruiting Gruppo Oncologico Italiano di Ricerca Clinica · Bari, BA and 24 other locations · NCT07363252

• Zorifertinib with Osimertinib for NSCLC with Meningeal Spread

  This study tests whether giving Zorifertinib together with Osimertinib is safe and effective for people with advanced NSCLC whose cancer has spread to the membranes around the brain and spine after Osimertinib treatment.

  Recruiting at 5 sites Phase 1 Alpha Biopharma (Jiangsu) Co., Ltd. · Beijing, Beijing Municipality and 4 other locations · NCT07361705

• Neoadjuvant sacituzumab tirumotecan with or without osimertinib for resectable EGFR‑mutated non‑small cell lung cancer

  This trial will test whether giving sacituzumab tirumotecan alone or together with osimertinib before surgery helps people with resectable EGFR‑mutated non‑small cell lung cancer.

  Recruiting Phase 2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Beijing · NCT07329322

• Telisotuzumab vedotin combined with osimertinib for progressive, incurable non-small cell lung cancer

  This trial tests whether adding the antibody-drug telisotuzumab vedotin to ongoing osimertinib can shrink tumors or slow growth in adults with progressive, incurable non-small cell lung cancer who have EGFR mutations.

  Recruiting Phase 2 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07323641

• Osimertinib plus savolitinib for EGFR-mutated lung cancer with low-level MET amplification

  This trial tests whether adding savolitinib to osimertinib helps people with EGFR-mutant non-small cell lung cancer who became resistant to osimertinib and have low-level MET amplification.

  Recruiting Phase 2 Qingdao Central Hospital · Qingdao · NCT07322783

• NXP900 plus osimertinib for advanced EGFR‑mutant non‑small cell lung cancer

  This trial will test whether adding NXP900 to osimertinib helps adults with advanced EGFR‑mutated non‑small cell lung cancer that has progressed on prior osimertinib.

  Recruiting at 5 sites Phase 1 Nuvectis Pharma, Inc. · Calverton, Maryland and 5 other locations · NCT07315113

• Osimertinib before radiation and as maintenance for chemo-ineligible Stage III EGFR‑mutant unresectable NSCLC

  This phase 2 trial will test whether giving osimertinib before definitive radiation and continuing it afterward helps adults with Stage III unresectable EGFR‑mutant NSCLC who can't or won't have chemotherapy.

  Recruiting at 18 sites Phase 2 AstraZeneca · Beijing and 19 other locations · NCT07295821

• Osimertinib Plus Chemotherapy After Distant Recurrence in EGFRm NSCLC

  This trial tests combining osimertinib with chemotherapy for patients whose non-small cell lung cancer with EGFR mutations has recurred after prior osimertinib in the adjuvant setting.

  Recruiting at 22 sites Phase 4 AstraZeneca · Beijing and 31 other locations · NCT07279935

• WSD0922-FU plus osimertinib for EGFR-mutant advanced NSCLC with C797S or new brain metastases

  This trial will test whether adding WSD0922-FU to osimertinib helps adults with advanced EGFR-mutant NSCLC who have the C797S resistance mutation or newly diagnosed brain metastases.

  Recruiting at 3 sites Phase 1/2 Wayshine Biopharm, Inc. · Fuzhou, Fujian and 2 other locations · NCT07206498

• Firmonertinib versus standard EGFR drugs as first treatment for advanced NSCLC with EGFR PACC mutations

  This trial tests whether daily firmonertinib works better than standard EGFR drugs (osimertinib or afatinib) as the first treatment for people with advanced NSCLC that has EGFR PACC mutations.

  Recruiting at 141 sites Phase 3 ArriVent BioPharma, Inc. · Fullerton, California and 140 other locations · NCT07185997

• IV telisotuzumab adizutecan versus standard treatment for adults with advanced EGFR‑mutated non‑squamous NSCLC

  This trial tests whether IV telisotuzumab adizutecan works better than standard treatment for adults with advanced non‑squamous non‑small cell lung cancer that has EGFR exon 19 deletion or L858R mutation.

  Recruiting at 117 sites Phase 2/3 AbbVie · Springdale, Arkansas and 116 other locations · NCT07155187

• Lurbinectedin with Osimertinib for transformed small cell lung cancer

  This study tests a drug combo (lurbinectedin plus osimertinib) to see if it can help adults whose EGFR-mutated non-small cell lung cancer has transformed into small cell lung cancer.

  Recruiting Phase 1/2 Indiana University · Indianapolis, Indiana · NCT07153055

• Boosting outcomes after osimertinib plus chemotherapy by adding surgery or focal radiation to the primary lung tumor

  This trial will test whether giving surgery or focused radiation to the main lung tumor helps people with EGFR-mutant advanced non-small cell lung cancer who have disease controlled after first-line osimertinib plus chemotherapy stay progression-free longer.

  Recruiting Phase 2 Pusan National University Hospital · Busan · NCT07073365

• Osimertinib-based adaptive treatment guided by ctDNA EGFR mutation monitoring for advanced EGFR-mutant NSCLC

  This Phase 2 trial tests whether using blood ctDNA to guide when to continue or step down osimertinib (with or without chemotherapy) can keep cancer controlled while reducing treatment side effects for people with advanced EGFR-mutant non-small cell lung cancer who clear EGFR mutations from plasma after initial therapy

  Recruiting Phase 2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT07058519

• Telisotuzumab adizutecan plus osimertinib for first-line treatment of advanced EGFR-mutated non-squamous NSCLC

  This test adds the investigational drug telisotuzumab adizutecan to osimertinib (or to osimertinib plus chemotherapy) to see if it helps adults with newly diagnosed advanced EGFR-mutated non-squamous non-small cell lung cancer and to check side effects.

  Recruiting at 63 sites Phase 2/3 AbbVie · Chandler, Arizona and 64 other locations · NCT07005102

• Evaluating furmonertinib with chemotherapy versus osimertinib for lung cancer with brain metastases

  This study is testing whether a new drug called furmonertinib combined with chemotherapy works better than osimertinib alone for people with lung cancer that has spread to the brain.

  Recruiting Phase 3 Allist Pharmaceuticals, Inc. · Guangdong, Guangzhou · NCT06970639

• WSD0922-FU for advanced non-small cell lung cancer with the C797S mutation

  This trial tests whether the oral drug WSD0922-FU can help adults with advanced non-small cell lung cancer whose tumors developed the C797S mutation after first-line osimertinib.

  Recruiting at 16 sites Phase 2 Wayshine Biopharm, Inc. · Weston, Florida and 15 other locations · NCT06868485

• Combining BL-B01D1 with Osimertinib for treating advanced lung cancer

  This study is testing whether adding a new drug called BL-B01D1 to osimertinib can help people with advanced lung cancer live better compared to just using osimertinib alone.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06838273

• Evaluating glumetinib and osimertinib for lung cancer after EGFR-TKI resistance

  This study is testing if a new combination of glumetinib and osimertinib can help people with lung cancer who have stopped responding to previous treatments.

  Recruiting Phase 3 Shanghai JMT-Bio Inc. · Beijing, Beijing Municipality · NCT06829459

• Combining JMT101 with Osimertinib for advanced lung cancer treatment

  This study is testing if adding a new drug called JMT101 to the standard treatment osimertinib can help people with advanced lung cancer live better and longer.

  Recruiting Phase 3 Shanghai JMT-Bio Inc. · Guangzhou · NCT06735391

• Evaluating genetic changes in lung cancer patients after oxitinib treatment

  This study is testing how genetic changes in lung cancer patients with specific mutations respond to three weeks of treatment with oxitinib.

  Recruiting Beijing Cancer Prevention & Treatment Society · Beijing · NCT06422546

• Neoadjuvant targeted therapy for lung cancer patients with specific mutations

  This study is testing if a targeted therapy called osimertinib can safely shrink tumors in lung cancer patients with specific mutations before surgery to help improve their treatment outcomes.

  Recruiting Phase 2 The First Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06383728

• Combining osimertinib and dalpiciclib for advanced lung cancer after treatment resistance

  This study is testing if combining two drugs, osimertinib and dalpiciclib, can help people with advanced lung cancer who have not responded to other treatments.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06363734

• First-line treatment for advanced non-small cell lung cancer with osimertinib and datopotamab deruxtecan

  This study is testing if combining two treatments, osimertinib and datopotamab deruxtecan, can help people with advanced non-small cell lung cancer that has certain mutations feel better compared to just using osimertinib alone.

  Recruiting at 133 sites Phase 3 AstraZeneca · Fountain Valley, California and 166 other locations · NCT06350097

• Combining GH21 Capsules with Osimertinib for Non-Small Cell Lung Cancer

  This study is testing if combining GH21 capsules with Osimertinib can help people with advanced Non-Small Cell Lung Cancer that has specific genetic changes.

  Recruiting at 4 sites Phase 1/2 Suzhou Genhouse Bio Co., Ltd. · Hefei, Anhui and 5 other locations · NCT06306456

• Comparing intra-pemetrexed with osimertinib for treating leptomeningeal metastasis in lung cancer

  This study is testing whether combining a specific type of chemotherapy with a targeted lung cancer drug can help people with leptomeningeal metastasis from lung cancer feel better compared to using the targeted drug alone.

  Recruiting Guangzhou Medical University · Huizhou, Guangdong · NCT06304441

• Intrathecal pemetrexed for leptomeningeal metastases after osimertinib in lung adenocarcinoma

  This trial will try giving pemetrexed directly into the spinal fluid to treat leptomeningeal metastases in people with EGFR‑mutant lung adenocarcinoma whose cancer progressed after double‑dose osimertinib.

  Recruiting Phase 2 Guangzhou Medical University · Huizhou, Guangdong · NCT06296745

• Evaluating resistance mechanisms to neoadjuvant osimertinib in lung cancer

  This study is testing if a drug called osimertinib can help people with certain types of lung cancer before their surgery and to see how the cancer might resist the treatment.

  Recruiting at 2 sites Phase 2 Sheba Medical Center · Ramat Gan, Israel and 1 other locations · NCT06206850

• Combining LMV-12 with Osimertinib for advanced lung cancer

  This study is testing a new treatment combining LMV-12 with osimertinib to see if it can help people with advanced lung cancer who haven't responded to other treatments.

  Recruiting Phase 1/2 Hunan Province Tumor Hospital · Changsha, Hunan · NCT06109558

• Observational study on osimertinib for lung cancer in Spain

  This study looks at how well osimertinib works for people in Spain with a specific type of lung cancer and different treatment backgrounds.

  Recruiting at 24 sites AstraZeneca · A Coruña and 25 other locations · NCT06068049

• Evaluating molecular factors and resistance mechanisms in lung cancer treatment

  This study is testing how well a specific lung cancer treatment works for patients with certain gene mutations and aims to find out why some patients might not respond to the treatment or have a relapse.

  Recruiting at 36 sites Intergroupe Francophone de Cancerologie Thoracique · Angers and 35 other locations · NCT06053099

• Pemetrexed injected into the spinal fluid for EGFR‑mutant lung cancer that has spread to the leptomeninges.

  This tests whether giving pemetrexed directly into the spinal fluid helps people with EGFR‑mutant non‑small cell lung cancer whose cancer has spread to the leptomeninges after osimertinib has stopped working.

  Recruiting Phase 2 Taipei Veterans General Hospital, Taiwan · Taipei, Taiwan · NCT05805631

• Osimertinib treatment after surgery for high-risk stage I lung cancer

  This study is testing if taking Osimertinib after surgery can help people with high-risk stage I lung cancer stay cancer-free longer.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT05686434

• Comparing targeted drug combinations for advanced lung cancer with specific gene changes

  This study is testing different combinations of targeted drugs to see if they can help people with advanced lung cancer that has specific gene changes live longer and feel better.

  Recruiting at 372 sites Phase 2 SWOG Cancer Research Network · Daphne, Alabama and 453 other locations · NCT05642572

• Using osimertinib to prevent progression of lung cancer nodules after surgery

  This study is testing if the drug osimertinib can help prevent lung cancer nodules from getting worse in patients who have had surgery for their cancer.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT05528458

• Combining osimertinib and carotuximab for advanced lung cancer treatment

  This study is testing a new combination of two drugs, osimertinib and carotuximab, to see if it can safely help people with advanced lung cancer caused by specific genetic changes.

  Recruiting at 5 sites Phase 1 Cedars-Sinai Medical Center · Beverly Hills, California and 4 other locations · NCT05401110

• Comparing TY-9591 and Osimertinib for advanced lung cancer

  This study is testing if a new drug called TY-9591 works better than the standard treatment Osimertinib for adults with advanced lung cancer that has specific genetic changes.

  Recruiting at 2 sites Phase 3 TYK Medicines, Inc · Changsha, Hunan and 1 other locations · NCT05382728

• Adding chemotherapy for patients with specific lung cancer mutations not responding to initial treatment

  This study is testing if adding chemotherapy to osimertinib can help patients with specific lung cancer mutations who aren't improving after starting osimertinib treatment.

  Recruiting at 16 sites Phase 2 Goethe University · Berlin and 15 other locations · NCT05281406

• Using Osimertinib for treating advanced EGFR-positive lung cancer

  This study is testing if the oral medication Osimertinib can help people with advanced EGFR-positive lung cancer who haven't had treatment before feel better and live longer.

  Recruiting National University Hospital, Singapore · Singapore · NCT05037331

• Evaluating Osimertinib with Early Stereotactic Radiosurgery for EGFR Mutated NSCLC with Brain Metastases

  This study is testing if combining a lung cancer drug called Osimertinib with early targeted radiation therapy can help people with EGFR-mutated non-small cell lung cancer and brain metastases live longer and maintain better brain function.

  Recruiting Hadassah Medical Organization · Jerusalem · NCT05033691

• Combining osimertinib with chemotherapy for lung cancer treatment

  This study is testing if combining a targeted lung cancer drug called osimertinib with chemotherapy can help people with specific EGFR mutations have better surgery results and improve their overall health.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT05011487

• Combining osimertinib and tegavivint for treating metastatic EGFR-mutant lung cancer

  This study is testing a new combination of two drugs, osimertinib and tegavivint, to see if it can help people with advanced lung cancer caused by EGFR mutations feel better and live longer.

  Recruiting Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT04780568

• Combining MRX-2843 and Osimertinib for Advanced Lung Cancer Treatment

  This study is testing whether combining two medications, MRX-2843 and osimertinib, can safely help people with advanced lung cancer caused by EGFR mutations.

  Recruiting Phase 1 Emory University · Atlanta, Georgia · NCT04762199

• Osimertinib to slow growth of remaining ground-glass nodules after lung cancer surgery

  This will try daily oral osimertinib (80 mg) to slow or stop growth of persistent ground-glass nodules in adults who had surgery for stage I lung adenocarcinoma with an L858R or exon 19 EGFR mutation.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Kangnamgu and 1 other locations · NCT04591002

• Combining gene therapy with osimertinib for advanced lung cancer patients

  This study is testing a new gene therapy combined with osimertinib to see if it can help people with advanced lung cancer who haven't responded to their current treatment.

  Recruiting at 8 sites Phase 1/2 Genprex, Inc. · Los Angeles, California and 9 other locations · NCT04486833

• Comparing osimertinib alone versus with chemotherapy for lung cancer

  This study is testing whether adding chemotherapy to osimertinib can help people with advanced lung cancer and an EGFR mutation feel better and live longer.

  Recruiting at 15 sites Phase 2 Memorial Sloan Kettering Cancer Center · Sacramento, California and 17 other locations · NCT04410796

• Retreating advanced lung cancer patients with osimertinib after chemotherapy

  This study is testing if giving osimertinib again can help people with advanced lung cancer who didn't respond to earlier treatments feel better and live longer.

  Recruiting at 10 sites Phase 2 London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Vancouver, British Columbia and 9 other locations · NCT04335292

• Combining osimertinib and bevacizumab for treating advanced EGFR-mutant lung cancer

  This study is testing if adding bevacizumab to osimertinib can help people with advanced EGFR-mutant lung cancer live longer and feel better compared to taking osimertinib alone.

  Recruiting at 328 sites Phase 3 National Cancer Institute (NCI) · Anchorage, Alaska and 603 other locations · NCT04181060

• Pemetrexed and carboplatin, with or without anlotinib, for advanced non-squamous NSCLC after osimertinib

  This trial tests whether adding anlotinib to pemetrexed plus carboplatin helps people with advanced non-squamous NSCLC whose cancer progressed on osimertinib.

  Recruiting Phase 2 Fudan University · Shenzhen, shenzhen · NCT04136535

• Using osimertinib to treat lung cancer with specific genetic mutations

  This study is testing if a medication called osimertinib can help people with advanced lung cancer that has a specific genetic mutation feel better and live longer.

  Recruiting at 215 sites Phase 2 National Cancer Institute (NCI) · Anchorage, Alaska and 346 other locations · NCT03191149

Quick answers

How many clinical trials of Osimertinib are recruiting right now?

62, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 30 countries. The most sites are in China (33 trials), United States (19 trials), South Korea (8 trials), Taiwan (7 trials), France (6 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 28, Phase 3: 11, Phase 1/2: 6, Phase 1: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →